15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Immunic Inc, 6 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $2.50 to $45.00 (about 18.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $15.79 sits 24% above the current $12.77. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.82 next quarter toward $-2.43 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Strong Buy
Strong Buy00%
Buy686%
Hold114%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Immunic Inc.
As of Sep, 5 of 6 firms rate IMUX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
IMUX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.82
Range $-1.26 – $-0.57 · 11 analysts · +17% YoY
Next period, 11 analysts expect Immunic Inc to earn $-0.82 a share (range $-1.26 – $-0.57), versus $-0.70 a year earlier. Full-year consensus is $-3.57, growing to $-2.43 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 11 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Immunic Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IMUX.
#1
Yatin Suneja
Guggenheim · Rank #21
Buy
$70.00+448.2% to target
Overall win rate
53%
+ Follow
#2
MC
Matthew Caufield
HC Wainwright & Co. · Rank #92
Buy
$22.00+72.3% to target
Overall win rate
54%
+ Follow
#3
Jason Kolbert
D. Boral Capital · Rank #416
Hold
No targeton IMUX
Overall win rate
22%
+ Follow
#4
Aydin Huseynov
Ladenburg Thalmann · Rank #432
Buy
$30.00+134.9% to target
Overall win rate
34%
+ Follow
#5
WW
William Wood
B. Riley Securities
Buy
$27.00+111.4% to target
Coverage
—
+ Follow
IMUX stock forecast FAQ
What is IMUX's average 12-month price target?+
The 6 analysts with a live target average $15.79 for Immunic Inc over the next 12 months, ranging from a $45.00 high to a $2.50 low.
Is IMUX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 7 analyst ratings, 6 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for IMUX?+
The Street-high target is $45.00 (Wedbush), and the Street-low is $2.50 (Stifel). The average of all 6 active targets is $15.79.
How many Wall Street analysts cover IMUX?+
7 analysts have an active rating on Immunic Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering IMUX?+
Among analysts who currently cover IMUX, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #21). Their current call is Buy with a $70.00 target.
What is Immunic Inc's projected EPS for next quarter?+
The consensus estimate is $-0.82 per share (range $-1.26 – $-0.57) across 11 analysts. Full-year EPS is projected at $-3.57, rising to $-2.43 the following year.
How much revenue is Immunic Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading IMUX lately?+
As of Sep, 5 of 6 firms rate IMUX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IMUX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
